Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions

Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news